Primary Immunodeficiency Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Primary Immunodeficiency Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic and the lockdown restrictions imposed by the government to avoid the spread of coronavirus have impacted the market growth. According to an article published in March 2022, titled ‘The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study’, the study was conducted in Iran from March 2020 to May 2021, and it has been found that among 90 primary immunodeficiency patients, 5 were having combined immunodeficiency disease and 4 were having primary antibody deficiencies (PADs). Additionally, as per a news published in January 2022, following SARS-CoV-2 infection, the United Kingdom Primary Immunodeficiency Network (UK PIN) compiled the health outcomes of 310 people with primary immunodeficiency diseases (PID) or secondary immunodeficiency diseases (SID) between March 2020 and July 2021 and it has been observed that 218 individuals were having PID and 92 SID. The COVID-19 virus poses a higher risk to people with primary and secondary immunodeficiencies because their immune systems are less capable of providing adequate defense against serious illness. Thus, impacting the market growth.

Certain factors that are propelling the market growth are the rising prevalence of immunodeficiency diseases and technological advancements in genetic therapy.

The increasing number of various immunodeficiency diseases is the key factor driving the market growth. For instance, according to an article published in January 2021, titled ‘Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities’, it has been observed that chronic obstructive pulmonary disease-asthma (51.5%) was statistically significantly more common as a comorbid diagnosis in the primary immunodeficiency disease population, followed by rheumatoid disease (14%), deficiency anemia (11.8%), hypothyroidism (21.2%), lymphoma (16.7%), neurologic disorders (9.7%), arrhythmias (19.9%), electrolyte disorders (23.6%), coagulopathies (16.9%), and weight loss (8.4%).

Additionally, according to an article in July 2021, titled ‘Rhinitis prevalence and association with atopic dermatitis, as per the meta-analysis the pooled prevalence of rhinitis was 40.5% in patients with atopic dermatitis and 18% in patients without atopic dermatitis, in 2020. In addition, as per the same source, the pooled prevalence of rhinitis and asthma was 14.2% in patients with atopic dermatitis. Thus, the rising innate immune disorders are expected to increase the need for effective immunodeficiency therapeutics which in turn is anticipated to propel the market growth over the forecast period.

Furthermore, the rising company activities in developing products are also expected to increase the market growth over the forecast period. For instance, in October 2020, the European Commission granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

However, the high cost of therapies and side effects associated with the treatment are likely to hinder the market growth over the forecast period.

Key Market TrendsGene Therapy Segment is Expected to Hold a Major Market Share in the Primary Immunodeficiency Therapeutics Market

The gene therapy segment is expected to witness significant growth in the primary immunodeficiency therapeutics market over the forecast period owing to the factors such as the rising prevalence of immunodeficiency disease and technological advancement in genetic therapy.

The purpose of gene addition or gene editing in gene therapy (GT) for primary immunodeficiency diseases (PIDs) is to insert a functioning copy of the damaged gene into the patient's hematopoietic stem cells (HSCs).

According to an article published in February 2021, titled ‘Gene Therapies for Primary Immune Deficiencies’, modified viruses such as lentiviral vectors showed an excellent safety profile without causing any genotoxicity. Several primary immunodeficiency diseases have been treated with gene therapy such as Adenosine Deaminase Severe Combined Immunodeficiency (SCID), X-linked SCID, Artemis SCID, Wiskott-Aldrich Syndrome, X-linked Chronic Granulomatous Disease, and Leukocyte Adhesion Deficiency-I. Such developments are expected to increase the development of therapeutics using gene therapy, thereby fuelling segment growth.

Furthermore, the rising prevalence of non-Hodgkin's lymphoma (NHL) is also contributing to segment growth. For instance, according to the 2022 statistics published by the American Cancer Society, about 80,470 people (44,120 males and 36,350 females) are expected to be diagnosed with NHL in 2022 in the United States. Also, a research study published in April 2020, titled 'Non-Hodgkin's lymphoma: A review' stated that Lymphomas constitute the third most common neoplasm in the head and neck region arising from the lymphoreticular system. This is expected to increase the demand for gene therapy treatments which is anticipated to boost the segment growth.

Therefore, owing to the aforesaid factors the segment is expected to witness growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant share in the primary immunodeficiency therapeutics market and show the same trend over the forecast period. Factors such as the rising prevalence of immunodeficiency diseases, growing technological advancements in genetic and stem cell therapy, and the presence of high healthcare expenditure and well-established healthcare infrastructure in the region.

According to the 2022 data published by the Organization for Economic Co-operation and Development (OECD), the United States' healthcare spending in 2021 was 17.8% of the total GDP of the country and Mexico’s health spending was 6.2% in 2020. Thus, the high healthcare spending is expected to increase company activities in developing effective and technologically advanced therapeutics for treating primary immunodeficiency diseases, thereby propelling the market growth.

The rising prevalence of immunodeficiency disease is the key factor driving the market growth. For instance, as per the 2022 statistics published by the United Nation Acquired Immunodeficiency Syndrome, 38.4 million people were living with HIV in 2021 in the United States and about 5.9 million people were not aware of their HIV status in 2021. Additionally, a 2020 report by the Food Allergy Research and Education estimates that 32 million residents in the United States have food allergies, including 5.6 million children under age 18. About 40% of children with food allergies are allergic to more than one food item.

Additionally, as per the data published by the American College of Allergy, Asthma, and Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost of more than USD 18 billion and more than 50 million Americans suffer from allergies each year. Also, as per the data published by the Centers for Disease Control and Prevention (CDC), in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis.

Similarly, according to the Government of Canada, in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Such a massive prevalence of immunodeficiency diseases among the population is expected to create the need for effective drugs for treatment and thus drive market growth.

Furthermore, the rising company’s focus on research and development activities as well as increasing product approvals in the region is expected to increase the market growth over the forecast period. For instance, in December 2021, the Food and Drug Administration granted a new indication for cutaquig (immune globulin, subcutaneous [Human]-hipp, 16.5% Solution; Octapharma) for the treatment of pediatric patients age 2 years and older with primary humoral immunodeficiency (PI). Also, in December 2021, the United States Food and Drug Administration approved Octapharma USA, cutaquig (Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution) for the treatment of pediatric patients aged 2 and older with primary humoral immunodeficiency (PI).

Therefore, owing to the aforesaid factors the segment is expected to witness growth over the forecast period.

Competitive Landscape

The primary immunodeficiency therapeutics market is consolidated with the presence of a few major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Baxter International Inc, Takeda Pharmaceutical Company Limited, CSL Ltd, Biotest AG, Octapharma AG, Kedrion Biopharma Inc, Bio Products Laboratory Limited, LFB group, Grifols S.A, and Lupin Pharmaceuticals.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.